Clinical Trials Logo
  1. Home
  2. Pancreatic Neuroendocrine Tumor
  3. NCT02624154
  4. Details
NCT02624154 Clinical Trial

Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival

Pancreatic Neuroendocrine Tumor Clinical Trial

Official title:
Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT02624154
Other study ID # SYSU 211
Secondary ID
Status Not yet recruiting
Phase N/A
First received November 30, 2015
Last updated December 4, 2015
Start date December 2015
Est. completion date December 2016

Study information
Verified date November 2015
Source First Affiliated Hospital, Sun Yat-Sen University
Contact Qinchang Chen, Doctor
Phone 18819430530
Email 337809622@qq.com
Is FDA regulated No
Health authority China: Health and Family Planning Commission of Guangdong Province
Study type Observational

Clinical Trial Summary

Investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor.

Description:

The variables including clinical characteristics, surgical data and pathological findings are examined by univariate and multivariate analyses.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 2
Est. completion date December 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 10 Years to 80 Years
Eligibility Inclusion Criteria:

- The patients with pancreatic neuroendocrine tumor underwent pancreatectomy

Exclusion Criteria:

- The patients with pancreatic neuroendocrine tumor did not undergo pancreatectomy

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Intervention

Procedure:
• pancreatectomy
Remove the pancreatic neuroendocrine tumor by surgery

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
First Affiliated Hospital, Sun Yat-Sen University

Outcome
Type Measure Description Time frame Safety issue
Primary The survival rate 3 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05566093 - EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors N/A
Completed NCT00970970 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Recruiting NCT05568017 - Neoadjuvant PRRT With Y-90-DOTATOC in pNET Phase 2
Not yet recruiting NCT06024343 - Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction N/A
Recruiting NCT03891784 - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Phase 2
Recruiting NCT03204019 - A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Phase 2
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Recruiting NCT05997056 - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors Phase 2
Not yet recruiting NCT06158516 - A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors Phase 2
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Recruiting NCT05040360 - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00576680 - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05610826 - Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver Phase 1/Phase 2
Active, not recruiting NCT03074513 - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Phase 2
Completed NCT03967951 - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Not yet recruiting NCT03435770 - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms N/A
Recruiting NCT04134832 - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Recruiting NCT05554744 - EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors N/A
Completed NCT02159989 - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1